Chromogranin-A expression in neoplastic neuroendocrine cells and prognosis in colorectal cancer
| Autor: | F De Lucchi, Giovanni Battista Secco, Pierfrancesco Bonfante, R. Fardelli, Elisabetta Campora, Daniela Gianquinto, Gabriella Lapertosa |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Colorectal cancer Adenocarcinoma 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Risk Factors Internal medicine medicine Chromogranins Humans chemistry.chemical_classification Regulation of gene expression biology business.industry Human gastrointestinal tract Chromogranin A General Medicine medicine.disease Prognosis Immunohistochemistry Neurosecretory Systems Survival Analysis Gene Expression Regulation Neoplastic medicine.anatomical_structure Logistic Models chemistry 030220 oncology & carcinogenesis Cancer research biology.protein business Glycoprotein Colorectal Neoplasms |
| Zdroj: | Tumori. 82(4) |
| ISSN: | 0300-8916 |
| Popis: | Aims Chromogranin-A (CG), a cytoplasmic glycoprotein, is one of the markers most frequently used to identify the presence of neuroendocrine cells in the human gastrointestinal tract. Several authors have identified a subgroup of colorectal cancer patients with a severe prognosis whose tumors contained neuroendocrine CG-positive cells. In the present study, CG expression in 100 patients with colorectal adenocarcinoma treated from January 1983 to December 1988 with potentially curative surgery was analyzed and correlated with other prognostic factors and 5-year survival rate. Methods Samples tested immunohistochemically for CG were divided into three groups: I) negative; II) less than 1 CG-positive cell/mm2; III) more than 1 CG-positive cell/mm2. Results Of 100 patients with primary colorectal adenocarcinoma, 79% had tumors comprised of CG-negative cells, 17% had rare CG-positive cells, and 4% of cases could be classified in group III. No significant relation between CG expression and location of primary tumor, bowel wall infiltration, stage of disease or tumor grade according to Broders and Jass was observed. The 5-year survival was 53% and 52% for CG-positive and CG-negative lesions, respectively. Survival of patients with Dukes-Kirklin stage C and D was comparable in patients with CG-positive (33.3%) and CG-negative (30%) tumors. Conclusions CG expression cannot, at present, be recommended as a marker to identify prognostic subgroups in colorectal cancer patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|